Anti-uPA Receptor/U-PAR antibody [EPR22173-257] - BSA and Azide free
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Monoclonal uPA Receptor/U-PAR antibody. Carrier free. Suitable for Flow Cyt, ICC/IF, IP and reacts with Human samples. Cited in 1 publication.
View Alternative Names
CD87, MO3, UPAR, PLAUR, Urokinase plasminogen activator surface receptor, U-PAR, uPAR, Monocyte activation antigen Mo3
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] - BSA and Azide free (AB240825)
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U937 (human histiocytic lymphoma cell line) cells, untreated or treated with TPA (200 nM, 72 hours), labeling uPA Receptor/U-PAR with ab221680 at 1/100 dilution followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).
Confocal image showing membranous staining in U937 cells treated with TPA (200 nM, 72 hours).
The expression of uPA Receptor/U-PAR is induced in PMA-stimulated U937 cells (PMID : 24999729).
The nuclear counterstain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.
Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol and sodium azide (ab221680).
- Flow Cyt
Unknown
Flow Cytometry - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] - BSA and Azide free (AB240825)
Flow cytometric analysis of U937 (human histiocytic lymphoma cell line) cell line treated with 200 nM TPA for 72 hours (red) or Untreated control (green) labeling uPA Receptor/U-PAR with ab221680 at 1/500 dilution compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.
The expression of uPA Receptor/U-PAR is induced in PMA-stimulated U937 cells (PMID : 24999729)
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab221680).
- IP
Unknown
Immunoprecipitation - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] - BSA and Azide free (AB240825)
uPA Receptor/U-PAR was immunoprecipitated from 0.35 mg of U937 (human histiocytic lymphoma cell line) treated with 200 nM TPA for 72 hours whole cell lysate with ab221680 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab221680 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/5000 dilution.
Lane 1 : U937 treated with 200 nM TPA for 72 hours whole cell lysate 10 μg (Input).
Lane 2 : ab221680 IP in U937 treated with 200 nM TPA for 72 hours whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab221680 in U937 treated with 200 nM TPA for 72 hours whole cell lysate.
Blocking/Dilution buffer : 5% NFDM/TBST.
Exposure time : 30 seconds.
The expression of uPA Receptor/U-PAR is induced in PMA-stimulated U937 cells and the molecular weight is consistent with what has been described in the literature (PMID : 24999729).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab221680).
All lanes:
Immunoprecipitation - Anti-uPA Receptor/U-PAR antibody [EPR22173-257] (<a href='/en-us/products/primary-antibodies/upa-receptor-u-par-antibody-epr22173-257-ab221680'>ab221680</a>)
Predicted band size: 37 kDa
false
Related conjugates and formulations (1)
-
Anti-uPA Receptor/U-PAR antibody [EPR22173-257]
Reactivity data
Product details
ab240825 is the carrier-free version of ab221680.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Biomarkers in medicine 18:523-533 PubMed39082977
2024
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com